Antiosteoporosis medication prescriptions after fragility fractures

Antiosteoporosis medication prescriptions after fragility fractures

A cohort study of nearly 40 000 older adults with fragility fracture found that fewer than one-third filled a prescription for antiosteoporosis medication in the year after hospital discharge.


Pharmacologic treatment for secondary osteoporotic fracture prevention is recommended after an initial fragility fracture of the hip, vertebrae, or pelvis, to reduce subsequent fracture risk. 


This study, conducted in Ontario, Canada, aimed to identify the extent of failing to provide antiosteoporosis medication following a fragility fracture. 37 874 patients were included, aged 66 years and older. The primary outcome was time to filling a prescription for an antiosteoporosis medication (alendronate, risedronate, etidronate, zoledronic acid, denosumab, raloxifene, or teriparatide) in the 365 days after hospital discharge for fracture.


The results of the study showed that fewer than one third (31.3%) filled an antiosteoporosis drug prescription in the year after discharge from hospital for fracture. Risedronate was the most commonly prescribed antiosteoporosis medication. Factors associated with filling a prescription for an antiosteoporosis medication included female gender, vertebral fracture and discharge to a rehabilitation hospital.


According to the authors: ‘Overall, our findings underscore the need for renewed and expanded health system efforts to improve postfracture prescribing of antiosteoporosis medications, particularly for patients at highest risk of undertreatment. These efforts could include implementation of fracture liaison services or multifaceted interventions (patient and clinician education, notifications, and reminders), which have the best evidence for improving prescribing rates’.

Read the article here!

Join the FFN

To help make the FFN vision a reality in your country, join the FFN – for free – today
Join FFN Today